Share
1,536 Posts.
lightbulb Created with Sketch. 303
clock Created with Sketch. 14/05/19
15:26
Share
Originally posted by dolcevita:
↑
The EU approval for the ADAPT products was TOTALY out of WP and the boards hands so in this instance I don't think any blame can be attributed . As for the direction they persued to market the ADAPT I feel this was a incredibly poor decision by management . Setting up a world wide network to market this product is just plain crazy , Maybe if AHZ was a well established and funded company and there were more products in the ADAPT range in would great but that's not the case . AHZ needed to partner to market the ADAPT and pick up that nice big pay cheque for the marketing rights . This would have given them the funds to drive the TAVR project deep into human trials , Successful human trials [for TAVR] will mean a partnering deal worth a more than most here think about . AGREED!! I can't agree with this more!!!
Expand
No Dol I think the crucial thing was the CE approval taking to long , This is probably one of the major factors ,WP and the board probably expected the ADAPT to be generating money out of Europe 12 mths ago . I dare say this is why targets have not been achieved and they have been paying a wage bill for staff with nothing to sell over there . You will never convince me that going it alone was a smart move , If they had plenty of capital and a few more products in the ADAPT range ok but this was not the case At the end of the day it is what it is now we just have to hope AHZ can get through the next 6 months , Hopefully they can soon start generating enough cash to keep it afloat .
(20min delay)